Condition · Hormones, Libido & Fertility
Libido / Sexual Desire
00
Background biology
Sexual desire is regulated by the melanocortin system, HPG axis, and dopaminergic pathways.
01
Evidence-ranked peptides
| Peptide | Use | Evidence |
|---|---|---|
| PT-141 PT-141 is a regulated peptide medicine with established evidence in defined indications. | Libido / Sexual Desire strong | Human4/5 Animal0/5 Safety3/5 3 verified refs |
| Kisspeptin Kisspeptin is an endogenous signalling peptide with physiological relevance; therapeutic administration remains molecule- and indication-specific. | Libido / Sexual Desire limited_to_moderate | Human3/5 Animal0/5 Safety3/5 3 verified refs |
| Oxytocin Oxytocin is an endogenous signalling peptide with physiological relevance; therapeutic administration remains molecule- and indication-specific. | Libido / Sexual Desire limited | Human0/5 Animal0/5 Safety0/5 0 verified refs |
| Melanotan Ii Melanotan Ii is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Libido / Sexual Desire low | Human0/5 Animal0/5 Safety0/5 0 verified refs |
02
Current standard management
conventional medicineManagement includes reviewing medical, psychological, relationship and medication contributors; counselling or sex therapy may be appropriate. In the United States, prescription options for selected premenopausal women with acquired, generalized HSDD include bremelanotide and flibanserin.
Medical disclaimer —Standard-of-care information is educational only. Do not change or start treatment based on Atlas content. Always consult a qualified clinician for personal medical decisions.
04
Linked mechanisms
biological pathways discussed for this condition- Melanocortin signallingneeds review
- HPG axis modulationneeds review
- Limbic sexual processingneeds review
- Oxytocin/social bonding signallingneeds review
- Dopaminergic reward signallingneeds review
- Melanocortin signallinglimited
- HPG axis modulationsupported
05
Research gaps
what we don't know yet- ·Long-term safety of chronic peptide use is unknown
- ·Optimal dosing and duration not established
- ·Effects in men vs women differ
- ·Long-term kisspeptin treatment data are lacking
- ·Evidence differs by sex and diagnosis
- ·Research peptides should not be equated with licensed medicines
03
Community observations
No approved community reports for this condition yet. Submit one.
Clinician discussion
Questions you can ask a qualified clinician
- What are the established evidence-based options for this condition?
- What monitoring is appropriate before considering any experimental intervention?
- What long-term safety data exists for peptide-based approaches?
- Are there licensed medicines relevant to my situation?
↳